GlassScriptPhysician profile
Yari Campbell
NPI 1144398678
$2,206.30
in general payments reported to CMS, 2019-2025
18 companies · $730 in 2025
The $730 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $81.46 · 2021: $357 · 2022: $86.74 · 2023: $32.95 · 2024: $338 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $891.40 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $262.02 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $180.34 | 2019-2021 | |
| Abbott Laboratories | $165.57 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $121.11 | 2021-2025 | Trelegy Ellipta |
| Pfizer INC. | $113.41 | 2019-2025 | |
| Lilly USA, LLC | $110.00 | 2024 | Zepbound |
| Gilead Sciences, INC. | $96.90 | 2019 | |
| Janssen Biotech, INC. | $51.25 | 2019 | |
| Amgen INC. | $50.01 | 2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $41.35 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.71 | 2025 | Caplyta |
| Currax Pharmaceuticals LLC | $27.64 | 2021-2022 | |
| Antares Pharma, INC. | $14.70 | 2025 | Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.23 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $12.60 | 2021 | |
| Theratechnologies INC. | $12.39 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yari Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.